Erill N¹, Colomer A¹, Verdú M², Román R¹, Vidal A², Condom E², Banús JM³, Cordón-Cardo C^1,2, Puig X^1,2.

¹BIOPAT. Grup Assistència, ²HISTOPAT Laboratoris & ³ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to define the TP53 status […]

 A. Colomer, N. Erill, M. Verdú, R. Román, A Vidal, X. Puig.

BIOPAT. Biopatologia Molecular, SL. Barcelona, Spain.

LOH 17p/TP53 and LOH 18q/DCC have been related to prognosis of colorectal adenocarcinomas. Since MSI-H tumors have a minor rate of TP53 mutations and rarely present allelic deletions, we intended to study these molecular features in a series of 197 primary tumors previously categorized for MSI status. Eighteen tumors out of 181 (10%) exhibited MSI-H. p53 alterations were approached by a combination of […]

Anna Colomer¹, Nadina Erill¹, Montse Verdú², Ruth Román¹, August Vidal^1,2, Xavier Puig^1,2.

¹BIOPAT, Biopatologia Molecular, Barcelona, Spain. ²Histopat Laboratoris, Barcelona, Spain.

Two different patterns have been described for colorectal tumorigenesis. The main one -affecting 85% of sporadic tumors- is based on the familial adenomatous polyposis (FAP) model, a multistep process that involves at least APC, K-RAS, DCC andTP53 genes. The second pathway shares its etiology with hereditary non-polyposis colorectal cancer (HNPCC), and is characterized by mutations at the mismatch repair genes (MMR) that lead […]